Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3

By /

Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.

Scroll to Top